MEDICINOVA ANNOUNCES COMPLETION OF ENROLLMENT IN GAD TRIAL

MediciNova has announced the completion of enrollment in its Phase II/III clinical trial of MN-305 in 416 patients with generalized anxiety disorder (GAD).

MN-305 is a novel, potent and highly selective serotonin 5-HT(1A) receptor agonist for the treatment of anxiety disorders beginning with GAD. This orally bioavailable compound has shown preliminary evidence of efficacy in animal models of anxiety and in an open-label study conducted in Japan by Mitsubishi Pharma in a group of patients with a variety of anxiety disorders. MN-305 was well tolerated in previous clinical studies involving over 800 volunteers and patients with either anxiety or mood disorders.